Photo Credit: Biomed Realty
Recommendation
I recommend long Acorda Therapeutics (ACOR) for 1-3 months aiming at a price target zone ranging from $20.23-$27.24 (currently trading at $15.95). The negative impact of generics erosion on Ampyra's sales has been overstated in my opinion, for which the company has used pricing strategy to buffer the damage. There's a large demand for Parkinson's Disease OFF period treatment worldwide, with about 350k patient population that is targeted by Inbrija. The company is poised to spin off Inbrija and focuses on its marketing and sales in the year